Business Wire

Velodyne Lidar and MOV.AI Partner to Provide Autonomous Solutions for Industrial and E-Commerce Robotics

31.8.2021 13:48:00 EEST | Business Wire | Press release

Share

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) and MOV.AI today announced the companies are collaborating to provide robot manufacturers with enterprise-grade automation solutions, including mapping, navigation, obstacle avoidance and risk avoidance. The MOV.AI Robotics Engine PlatformTM, combined with Velodyne’s lidar sensors, addresses the growing demand for automation in dynamic collaborative environments such as e-commerce, logistics, manufacturing and hospitals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005234/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Velodyne Lidar and MOV.AI are collaborating to provide robot manufacturers with enterprise-grade automation solutions, including mapping, navigation, obstacle avoidance and risk avoidance. (Photo: MOV.AI)

The MOV.AI Robotics Engine PlatformTM, powered by Velodyne’s Puck™ lidar sensors, delivers advanced tools that allow autonomous mobile robots (AMR) manufacturers and integrators to address the challenges of safely moving in changing and unstructured environments like material handling and warehouse logistics. These markets are being driven by the dramatic growth of e-commerce. For instance, the pandemic helped propel U.S. online sales to $791 billion in 2020, up 32 percent from the prior year, according to the U.S. Department of Commerce.

The Robotics Engine Platform helps AMR manufacturers quickly develop and deploy robots that can operate in dynamic environments in which humans, manual machines and robots work side by side. The platform leverages the performance and reliability of the Puck sensor to allow mobile robots to traverse outside controlled situations and safely function in unfamiliar and unpredictable settings. The Puck’s compact form factor enables it to be embedded easily into robots. The sensor delivers high accuracy in complex indoor and outdoor environments.

The MOV.AI ROS-based Robotics Engine PlatformTM provides AMR manufacturers and automation integrators with the enterprise-grade tools they need for advanced automation. It includes a visual Integrated Development Environment (IDE), off the shelf algorithms and integrations, fleet management, flexible interfaces with warehouse environments such as ERP and WMS, and cyber-security compliance. The solution provides ±2 cm accuracy for a 65 percent dynamic environment.

“Adding MOV.AI and Velodyne technologies to TUGBOT.ai provided our robot with an off-the-shelf, high-accuracy navigation and localization solution for the high and dynamic environments where we are deploying our AMRs,” said Fernando Freitas, CEO at RoboSavvy, manufacturer of the AMR TUGBOT.ai. “Using lidar-based SLAM enables TUGBOT.ai to navigate safely among people and other vehicles with accurate and consistent performance.”

“MOV.AI’s mission is to simplify collaborative robot development and to provide AMR manufacturers and integrators with everything they need to develop and operate great robots,” said Motti Kushnir, MOV.AI’s CEO. “Through the collaboration with Velodyne, we are able to offer our customers advanced SLAM navigation powered by the Puck, one of the world’s leading lidar sensors. Use of our Robotics Engine Platform allows AMR manufacturers to quickly implement state-of-the-art navigation, while leaving them the ability to customize it to their needs.”

“We are very excited about the collaboration with MOV.AI and integration of our lidar sensors into the Robotics Engine Platform, including future expansion to our solid state Velarray and Velabit products,” said Erich Smidt, Executive Director of Europe, Velodyne Lidar. “There is a growing demand for automation and integration of our sensors into collaborative robots. We see extensive potential in this space, with the global AMR market size is expected to reach USD 8.70 billion in 2028, with a CAGR of 23.7 percent from 2021 to 2028, according to Fortune Business Insights. Partnering with MOV.AI can enable us to bring safety, efficiency and sustainability into the industrial sector on a large, global scale.”

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

About MOV.AI

MOV.AI is changing AMRs as we know them.

It provides AMR manufacturers and integrators with the tools they need to create enterprise-grade robots quickly, allowing users to benefit from automation products that are as flexible as the age we live in.

MOV.AI is a Robotics Engine platform based on ROS and packaged in an intuitive web based interface. It contains everything needed to build, deploy and operate intelligent robots. MOV.AI completely changes the way Autonomous Mobile Robots are developed, in terms of time to market, cost and flexibility.

Forward Looking Statements

This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Velodyne Investor Relations
InvestorRelations@velodyne.com

Velodyne Media
Codeword
Liv Allen
velodyne@codewordagency.com

MOV.AI Media
Ruth Zamir
pr@g2mteam.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye